1
|
Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. Eur J Pharm Biopharm 2016; 109:214-223. [DOI: 10.1016/j.ejpb.2016.10.006] [Citation(s) in RCA: 98] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 09/09/2016] [Accepted: 10/22/2016] [Indexed: 01/31/2023]
|
2
|
Vandewalle A, Tourneur E, Bens M, Chassin C, Werts C. Calcineurin/NFAT signaling and innate host defence: a role for NOD1-mediated phagocytic functions. Cell Commun Signal 2014; 12:8. [PMID: 24479879 PMCID: PMC3910266 DOI: 10.1186/1478-811x-12-8] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2013] [Accepted: 01/23/2014] [Indexed: 12/12/2022] Open
Abstract
The calcineurin/nuclear factor of activated T cells (NFATs) signaling pathway plays a central role in T cell mediated adaptive immune responses, but a number of recent studies demonstrated that calcineurin/NFAT signaling also plays a key role in the control of the innate immune response by myeloid cells. Calcineurin inhibitors, such as cyclosporine A (CsA) and tacrolimus (FK506), are commonly used in organ transplantation to prevent graft rejection and in a variety of immune diseases. These immunosuppressive drugs have adverse effects and significantly increase host's susceptibility towards bacterial or fungal infections. Recent studies highlighted the role of NFAT signaling in fungal infection and in the control of the pattern recognition receptor nucleotide-binding oligomerization domain-containing protein 1 (NOD1), which predominantly senses invasive Gram-negative bacteria and mediates neutrophil phagocytic functions. This review summarises some of the current knowledge concerning the role of NFAT signaling in the innate immune response and the recent advances on NFAT-dependent inhibition of NOD1-mediated innate immune response caused by CsA, which may contribute to sensitizing transplant recipients to bacterial infection.
Collapse
Affiliation(s)
- Alain Vandewalle
- Centre de Recherche sur l'Inflammation (CRI), UMRS 1149 et Groupe ATIP-AVENIR, Université Denis Diderot - Paris 7, Paris, France.
| | | | | | | | | |
Collapse
|
3
|
Tourneur E, Ben Mkaddem S, Chassin C, Bens M, Goujon JM, Charles N, Pellefigues C, Aloulou M, Hertig A, Monteiro RC, Girardin SE, Philpott DJ, Rondeau E, Elbim C, Werts C, Vandewalle A. Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients. PLoS Pathog 2013; 9:e1003152. [PMID: 23382681 PMCID: PMC3561241 DOI: 10.1371/journal.ppat.1003152] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2012] [Accepted: 12/08/2012] [Indexed: 12/12/2022] Open
Abstract
Acute pyelonephritis (APN), which is mainly caused by uropathogenic Escherichia coli (UPEC), is the most common bacterial complication in renal transplant recipients receiving immunosuppressive treatment. However, it remains unclear how immunosuppressive drugs, such as the calcineurin inhibitor cyclosporine A (CsA), decrease renal resistance to UPEC. Here, we investigated the effects of CsA in host defense against UPEC in an experimental model of APN. We show that CsA-treated mice exhibit impaired production of the chemoattractant chemokines CXCL2 and CXCL1, decreased intrarenal recruitment of neutrophils, and greater susceptibility to UPEC than vehicle-treated mice. Strikingly, renal expression of Toll-like receptor 4 (Tlr4) and nucleotide-binding oligomerization domain 1 (Nod1), neutrophil migration capacity, and phagocytic killing of E. coli were significantly reduced in CsA-treated mice. CsA inhibited lipopolysaccharide (LPS)-induced, Tlr4-mediated production of CXCL2 by epithelial collecting duct cells. In addition, CsA markedly inhibited Nod1 expression in neutrophils, macrophages, and renal dendritic cells. CsA, acting through inhibition of the nuclear factor of activated T-cells (NFATs), also markedly downregulated Nod1 in neutrophils and macrophages. Silencing the NFATc1 isoform mRNA, similar to CsA, downregulated Nod1 expression in macrophages, and administration of the 11R-VIVIT peptide inhibitor of NFATs to mice also reduced neutrophil bacterial phagocytosis and renal resistance to UPEC. Conversely, synthetic Nod1 stimulating agonists given to CsA-treated mice significantly increased renal resistance to UPEC. Renal transplant recipients receiving CsA exhibited similar decrease in NOD1 expression and neutrophil phagocytosis of E. coli. The findings suggest that such mechanism of NFATc1-dependent inhibition of Nod1-mediated innate immune response together with the decrease in Tlr4-mediated production of chemoattractant chemokines caused by CsA may contribute to sensitizing kidney grafts to APN.
Collapse
Affiliation(s)
- Emilie Tourneur
- INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon, Université Paris 7 - Denis Diderot, Paris, France
| | - Sanae Ben Mkaddem
- INSERM U699, Paris, France; Université Paris 7 - Denis Diderot, Paris, France
| | - Cécilia Chassin
- INSERM U699, Paris, France; Université Paris 7 - Denis Diderot, Paris, France
| | - Marcelle Bens
- INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon, Université Paris 7 - Denis Diderot, Paris, France
| | - Jean-Michel Goujon
- Université de Poitiers, CHU Poitiers; Service d'Anatomie et Cytologie Pathologiques, Poitiers, France
| | - Nicolas Charles
- INSERM U699, Paris, France; Université Paris 7 - Denis Diderot, Paris, France
| | | | - Meryem Aloulou
- INSERM U699, Paris, France; Université Paris 7 - Denis Diderot, Paris, France
| | - Alexandre Hertig
- Service Urgences Néphrologiques et Transplantation Rénale and INSERM U702, Hôpital Tenon; Université Paris 6 - Pierre et Marie Curie, Paris, France
| | - Renato C. Monteiro
- INSERM U699, Paris, France; Université Paris 7 - Denis Diderot, Paris, France
| | - Stephen E. Girardin
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | - Dana J. Philpott
- Department of Immunology, University of Toronto, Toronto, Canada
| | - Eric Rondeau
- Service Urgences Néphrologiques et Transplantation Rénale and INSERM U702, Hôpital Tenon; Université Paris 6 - Pierre et Marie Curie, Paris, France
| | - Carole Elbim
- INSERM UMR-S 945, Hôpital Pitié-Salpêtrière, Université Paris 6 - Pierre et Marie Curie, Paris, France
| | - Catherine Werts
- Institut Pasteur, G5 Biologie et Génétique des Parois Bactériennes, Paris, France
| | - Alain Vandewalle
- INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon, Université Paris 7 - Denis Diderot, Paris, France
- * E-mail:
| |
Collapse
|
4
|
Beceiro A, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Bou G, Pachón J. In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Antimicrob Agents Chemother 2009; 53:4298-304. [PMID: 19635957 PMCID: PMC2764194 DOI: 10.1128/aac.00320-09] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2009] [Revised: 05/11/2009] [Accepted: 07/15/2009] [Indexed: 11/20/2022] Open
Abstract
Clavulanic acid (CLA) exhibits low MICs against some Acinetobacter baumannii strains. The present study evaluates the efficacy of CLA in a murine model of A. baumannii pneumonia. For this purpose, two clinical strains, Ab11 and Ab51, were used; CLA MICs for these strains were 2 and 4 mg/liter, respectively, and the imipenem (IPM) MIC was 0.5 mg/liter for both. A pneumonia model in C57BL/6 mice was used. The CLA dosage (13 mg/kg of body weight given intraperitoneally) was chosen to reach a maximum concentration of the drug in serum similar to that in humans and a time during which the serum CLA concentration remained above the MIC equivalent to 40% of the interval between doses. Six groups (n = 15) were inoculated with Ab11 or Ab51 and were allocated to IPM or CLA therapy or to the untreated control group. In time-kill experiments, CLA was bactericidal only against Ab11 whereas IPM was bactericidal against both strains. CLA and IPM both decreased bacterial concentrations in lungs, 1.78 and 2.47 log10 CFU/g (P < or = 0.001), respectively, in the experiments with Ab11 and 2.42 and 2.28 log10 CFU/g (P < or = 0.001), respectively, with Ab51. IPM significantly increased the sterility of blood cultures over that for the controls with both strains (P < or = 0.005); CLA had the same effect with Ab51 (P < 0.005) but not with Ab11 (P = 0.07). For the first time, we suggest that CLA may be used for the treatment of experimental severe A. baumannii infections.
Collapse
Affiliation(s)
- Alejandro Beceiro
- Servicio de Microbiología-Unidad de Investigación, Complejo Hospitalario Universitario Juan Canalejo, 15006 La Coruña, Spain
| | | | | | | | | | | |
Collapse
|
5
|
Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol 2008; 21:153-60. [PMID: 18336741 DOI: 10.1177/039463200802100117] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Antimicrobial agents and polymorphonuclear cells (PMNs) have the potential to interact in such a way that improve the therapy for infectious diseases. In immunocompromised patients highly susceptible to microbial infections with high morbidity and mortality, several metabolic and functional alterations in PMNs, mostly related to microbicidal activity, are observed. Therefore, the antibiotic of choice should have a good antimicrobial effect without impairing host defences. The aim of this study is to evaluate in vitro effects of sub-inhibiting fosfomycin tromethamine (FT) concentrations on the primary functions of PMNs from healthy subjects and immunocompromised patients (haemodialysed and renal transplant recipients), against an ESBL-producing Escherichia coli, the most common aetiological agent in urinary tract infections (UTIs). FT is considered a first line drug in the eradication of UTIs due to its appropriate antimicrobial spectrum, oral bioavailability and minimal risk of microbial resistance. Our results provide evidence that FT is able to induce enhancement of the depressed phagocytic response of PMNs from patients on chronic haemodialysis and from renal transplant recipients, restoring their primary functions in vitro against ESBL-producing E. coli. All these data permit the conclusion that uremic-infected patients might additionally benefit from the immunomodulating properties of FT.
Collapse
Affiliation(s)
- V Tullio
- Department of Public Health and Microbiology, University of Turin, Turin, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Bicker H, Höflich C, Wolk K, Vogt K, Volk HD, Sabat R. A Simple Assay to Measure Phagocytosis of Live Bacteria. Clin Chem 2008; 54:911-5. [DOI: 10.1373/clinchem.2007.101337] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Abstract
Background: The phagocytosis of pathogens is essential for fighting infections. No assay is available, however, to measure both engulfment and degradation of bacteria under conditions similar to those in vivo. We sought to develop a flow cytometric assay to measure the engulfment and degradation of live bacteria by human blood monocytes and granulocytes.
Methods: We generated enhanced green fluorescent protein (EGFP)-expressing Eschericha coli by transforming E. coli with the plasmid vector pEGFP. We used these bacteria in a flow cytometric assay to measure both engulfment and degradation of living bacteria by monocytes and granulocytes in human whole blood from fresh, heparinized venous blood samples. To determine whether the test detected differences between healthy individuals and patients with secondary immunodeficiencies, we compared the phagocytosis of monocytes and granulocytes measured in blood samples from immunosuppressed kidney transplantation patients and from patients with postoperative sepsis in immunoparalysis with phagocytosis measured in samples from age-matched healthy individuals.
Results: In samples from healthy individuals, we found that in both monocytes and granulocytes bacterial degradation was negatively correlated with the age of the sample donor. Furthermore, we detected decreased bacterial engulfment in granulocytes from septic patients and decreased bacterial degradation in monocytes from immunosuppressed kidney transplantation patients.
Conclusions: This flow cytometric assay measures the engulfment and degradation of live bacteria by human blood monocytes and granulocytes. By means of this assay we detected significant differences between healthy controls and patients with secondary immunodeficiencies that may contribute to the increased incidence of infection complications seen in these patients.
Collapse
Affiliation(s)
| | | | - Kerstin Wolk
- Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany
| | | | | | - Robert Sabat
- Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany
| |
Collapse
|
7
|
Sánchez Navarro A. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2006; 44:1097-115. [PMID: 16231964 DOI: 10.2165/00003088-200544110-00001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The pharmacokinetic properties of amoxicillin and clavulanic acid when used alone or in combination are extensively reviewed and discussed in this article. The reported data support a nonlinear absorption process for amoxicillin. Saturable transport mechanisms, limited solubility and the existence of an absorption window are possibly involved in the gastrointestinal absorption of this antibacterial, all leading to a decrease in the peak plasma concentration (Cmax)/dose ratio, a prolongation of the time to reach Cmax, and broad variability for high doses of amoxicillin. Data available in the literature also suggest a possible interaction between amoxicillin and clavulanic acid that might decrease the absolute bioavailability of clavulanic acid. In the present review the intrinsic pharmacodynamics of each drug, together with the synergism produced by the amoxicillin/clavulanic acid association, are also reviewed and analysed. Not only beta-lactamase-producing strains, but also Streptococcus pneumoniae strains, seem to be more efficiently eradicated by the association of amoxicillin and clavulanic acid, and a relevant post-antibacterial effect and post-beta-lactamase inhibitor effect are likely to operate when amoxicillin is administered together with clavulanic acid. The principles of pharmacokinetic/pharmacodynamic analysis applied to amoxicillin are reviewed, with special emphasis being placed on the results obtained from in vitro studies and animal models regarding the new pharmacokinetically enhanced formulation. Theoretical considerations concerning the efficacy of this formulation provided by the application of pharmacokinetic/pharmacodynamic analysis to the scarce pharmacokinetic data available are also included. The broad pharmacokinetic variability of both amoxicillin and clavulanic acid, particularly when administered together and at high doses of amoxicillin, is highlighted and the interest in considering this aspect to improve predictions based on pharmacokinetic/pharmacodynamic analyses for the new formulations is indicated. Methodological recommendations such as the Monte Carlo simulation are proposed in order to obtain more realistic predictions in clinical practice.
Collapse
|
8
|
Dufour V, Millon L, Faucher JF, Bard E, Robinet E, Piarroux R, Vuitton DA, Meillet D. Effects of a short-course of amoxicillin/clavulanic acid on systemic and mucosal immunity in healthy adult humans. Int Immunopharmacol 2005; 5:917-28. [PMID: 15778127 DOI: 10.1016/j.intimp.2005.01.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2004] [Revised: 09/03/2004] [Accepted: 01/21/2005] [Indexed: 11/29/2022]
Abstract
Although amoxicillin/clavulanic acid (AMC) is the most frequently administered antibiotic in France, its in vivo effects on immunity in healthy adults have never, to our knowledge, been described. Eighteen healthy adult male volunteers, 25+/-6 years old, were treated for 5 days with oral amoxicillin (1 g) /clavulanate potassium (125 mg), two times daily. Systemic and local intestinal immunity parameters were sequentially explored before, during and after the antibiotic treatment. No significant differences were obtained for transudation markers (albumin and alpha1-antitrypsin) in sera, feces and saliva, showing that AMC did not induce inflammatory reaction. Phagocytosis, peripheral blood cell subsets, intracellular interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production by natural killer (NK) cells and cytotoxic T lymphocytes, intracellular TNF-alpha production by monocytes showed no significant differences throughout the trial. In fecal outputs, no significant differences were found in secretory immunoglobulin A (S-IgA), lactoferrin (Lf), lysozyme (Lz) and transforming growth factor (TGF)-beta1. In sera, concentrations of total IgA (T-IgA), S-IgA, IgM, Lf and Lz did not show any significant variations throughout the study, whereas concentrations of IgG were slightly but significantly reduced 15 days after AMC treatment. In saliva, concentrations of T-IgA were slightly but significantly higher, whereas S-IgA concentrations were unchanged. Our results showed that oral AMC intake did not induce any significant adverse effects on immunity in adult humans.
Collapse
Affiliation(s)
- Vinciane Dufour
- Unité Santé et Environnement Rural, UFR Sciences Médicales et Pharmaceutiques, Université de Franche-Comté, Besançon, France.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Hutchinson P, Chadban SJ, Atkins RC, Holdsworth SR. Laboratory assessment of immune function in renal transplant patients. Nephrol Dial Transplant 2003; 18:983-9. [PMID: 12686675 DOI: 10.1093/ndt/gfg190] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Advances in immunosuppression have made renal transplantation an effective therapy for end stage renal failure; with low rejection rates and long graft survival times. However, the major adverse consequences, infection and malignancy have not diminished. To predict this risk a score of immune competence has been developed from the simultaneous laboratory assessment of multiple parameters of immune function. METHODS The immune status of 152 transplant recipients (138 renal and 14 pancreas/renal) was assessed by measurement of lymphocyte subsets, mitogen-induced T-cell proliferative responses, neutrophil phagocytic capacity and reactive oxygen species (ROS) generation. A scoring system was devised based on the average number of these parameters below 10th percentile of normal. RESULTS The most common abnormality was B-cell lymphopenia (85%) followed by reduced neutrophil ROS production (63% of patients), NK cell lymphopenia (50%), lymphocyte mitogen response (49%) and CD4 number (23%). The abnormalities were unrelated to the duration of immunosuppression (up to 15 years), and variable combinations of cyclosporine A, azathioprine, prednisolone and mycophenolate mofetil (MMF) (except for a consistent reduction in lymphocyte mitogen response in MMF treated patients). Retrospective comparison of infective episodes showed a significantly greater index of infections in patients with the worst score compared with a normal score. CONCLUSIONS The data suggests that this quantification of immune function may allow assessment of the level of host immune defence reflecting the level of drug-induced immunosuppression and thus risks of immunosuppressive complications.
Collapse
Affiliation(s)
- Paul Hutchinson
- Department of Clinical Immunology, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia.
| | | | | | | |
Collapse
|